Management of hyperuricemia in gout: focus on febuxostat

Mattheus K Reinders1, Tim L Th A Jansen21Clinical Pharmacy, Atrium Medisch Centrum Parkstad, Heerlen, The Netherlands; 2Rheumatology, Medisch Centrum Leeuwarden, Leeuwarden, The NetherlandsAbstract: Gout is the most common inflammatory arthritis in an elderly population, and can be diagnosed with ab...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mattheus K Reinders, Tim L Th A Jansen
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	aging febuxostat hyperuricemia gout pharmacotherapy xanthine oxidase Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/04df54d197474fc8aed671cf4ab3016b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:04df54d197474fc8aed671cf4ab3016b
record_format	dspace
spelling	oai:doaj.org-article:04df54d197474fc8aed671cf4ab3016b2021-12-02T04:22:51ZManagement of hyperuricemia in gout: focus on febuxostat1178-1998https://doaj.org/article/04df54d197474fc8aed671cf4ab3016b2010-01-01T00:00:00Zhttps://www.dovepress.com/management-of-hyperuricemia-in-gout-focus-on-febuxostat-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Mattheus K Reinders1, Tim L Th A Jansen21Clinical Pharmacy, Atrium Medisch Centrum Parkstad, Heerlen, The Netherlands; 2Rheumatology, Medisch Centrum Leeuwarden, Leeuwarden, The NetherlandsAbstract: Gout is the most common inflammatory arthritis in an elderly population, and can be diagnosed with absolute certainty by polarization microscopy. However, diagnosis may be challenging because atypical presentations are more common in the elderly. Management of hyperuricemia in the elderly with gout requires special consideration because of co-medication, contra-indications, and risk of adverse reactions. Urate-lowering agents include allopurinol and uricosuric agents. These also must be used sensibly in the elderly, especially when renal function impairment is present. However, if used at the lowest dose that maintains the serum urate level below 5.0 to 6.0 mg/dL (0.30 to 0.36 mmol/L), the excess urate in the body will eventually be eliminated, acute flares will no longer occur, and tophi will resolve. Febuxostat, a new xanthine oxidase inhibitor, is welcomed, as few alternatives for allopurinol are available. Its pharmacokinetics and pharmacodynamics are not significantly altered in patients with moderate renal function or hepatic impairment. Its antihyperuricemic efficacy at 80 to 120 mg/day is better than “standard dosage” allopurinol (300 mg/day). Long-term safety data and efficacy data on tophus diminishment and reduction of gout flares have recently become available. Febuxostat may provide an important option in patients unable to use allopurinol, or refractory to allopurinol.Keywords: aging, febuxostat, hyperuricemia, gout, pharmacotherapy, xanthine oxidaseMattheus K ReindersTim L Th A JansenDove Medical Pressarticleagingfebuxostathyperuricemiagoutpharmacotherapyxanthine oxidaseGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 5, Pp 7-18 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	aging febuxostat hyperuricemia gout pharmacotherapy xanthine oxidase Geriatrics RC952-954.6
spellingShingle	aging febuxostat hyperuricemia gout pharmacotherapy xanthine oxidase Geriatrics RC952-954.6 Mattheus K Reinders Tim L Th A Jansen Management of hyperuricemia in gout: focus on febuxostat
description	Mattheus K Reinders1, Tim L Th A Jansen21Clinical Pharmacy, Atrium Medisch Centrum Parkstad, Heerlen, The Netherlands; 2Rheumatology, Medisch Centrum Leeuwarden, Leeuwarden, The NetherlandsAbstract: Gout is the most common inflammatory arthritis in an elderly population, and can be diagnosed with absolute certainty by polarization microscopy. However, diagnosis may be challenging because atypical presentations are more common in the elderly. Management of hyperuricemia in the elderly with gout requires special consideration because of co-medication, contra-indications, and risk of adverse reactions. Urate-lowering agents include allopurinol and uricosuric agents. These also must be used sensibly in the elderly, especially when renal function impairment is present. However, if used at the lowest dose that maintains the serum urate level below 5.0 to 6.0 mg/dL (0.30 to 0.36 mmol/L), the excess urate in the body will eventually be eliminated, acute flares will no longer occur, and tophi will resolve. Febuxostat, a new xanthine oxidase inhibitor, is welcomed, as few alternatives for allopurinol are available. Its pharmacokinetics and pharmacodynamics are not significantly altered in patients with moderate renal function or hepatic impairment. Its antihyperuricemic efficacy at 80 to 120 mg/day is better than “standard dosage” allopurinol (300 mg/day). Long-term safety data and efficacy data on tophus diminishment and reduction of gout flares have recently become available. Febuxostat may provide an important option in patients unable to use allopurinol, or refractory to allopurinol.Keywords: aging, febuxostat, hyperuricemia, gout, pharmacotherapy, xanthine oxidase
format	article
author	Mattheus K Reinders Tim L Th A Jansen
author_facet	Mattheus K Reinders Tim L Th A Jansen
author_sort	Mattheus K Reinders
title	Management of hyperuricemia in gout: focus on febuxostat
title_short	Management of hyperuricemia in gout: focus on febuxostat
title_full	Management of hyperuricemia in gout: focus on febuxostat
title_fullStr	Management of hyperuricemia in gout: focus on febuxostat
title_full_unstemmed	Management of hyperuricemia in gout: focus on febuxostat
title_sort	management of hyperuricemia in gout: focus on febuxostat
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/04df54d197474fc8aed671cf4ab3016b
work_keys_str_mv	AT mattheuskreinders managementofhyperuricemiaingoutfocusonfebuxostat AT timlthajansen managementofhyperuricemiaingoutfocusonfebuxostat
_version_	1718401228356976640

Management of hyperuricemia in gout: focus on febuxostat

Ejemplares similares